Clinical trials: Movement Abnormalities
Parkinson's Disease With Dementia
The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's Disease
The project will investigate the effect of pharmacological and electric modulation of N-methyl-D-aspartate (NMDA) pathway on the cognitive flexibility and volitional movement preparation in patients with Parkinson's disease (PD).
- Trial name
- NCT01785628
- Testing
- Sarcosine Capsule
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- China Medical University Hospital
Idiopathic Parkinson Disease
Voice Treatment for Parkinson's Disease
This study addresses several issues related to the clinical management of speech and voice disorders associated with Parkinson's disease.
- Trial name
- NCT03700684
- Testing
- Lee Silverman Voice Treatment, SpeechVive, Control
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- University of Massachusetts, Amherst
Alzheimer's Disease, Huntington's Disease
A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users
Dimebon will not exhibit abuse potential when compared to placebo or a positive control (alprazolam).
- Trial name
- NCT00975481
- Testing
- dimebon, alprazolam
- Volunteers
- 36 people
- Sponsor
- Pfizer
Parkinson's Disease
Real-PD Trial: Development of Clinical Prognostic Models for Parkinson's Disease
Background: Long-term management of Parkinson's disease (PD) does not reach its full potential due to lack of knowledge about disease progression.
- Trial name
- NCT02474329
- Testing
- Clinical assessment, Fox Insight self-monitoring android app and falls detector
- Where
- Netherlands
- Volunteers
- 304 people
- Sponsor
- Radboud University Medical Center
Parkinson Disease, Movement Disorders
Dyskinesia in Parkinson's Disease (Study P04501)
The purpose of the study is to assess the efficacy and safety of a range of doses of SCH 420814 (preladenant) when used together with a stable dose of L-dopa/dopa decarboxylase inhibitor to treat Parkinson's disease.
- Conditions
- Parkinson Disease, Movement Disorders, Central Nervous System Diseases, Neurodegenerative Diseases
- Trial name
- NCT00406029
- Testing
- Preladenant, L-dopa, Other Parkinson's Disease treatments
- Volunteers
- 253 people
- Sponsor
- Merck Sharp & Dohme LLC
Parkinson's Disease
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
This is a study to compare the efficacy of IPX066 and CLE in subjects with advanced Parkinson's disease.
- Trial name
- NCT01130493
- Testing
- IPX066, CLE
- Where
- 24 sites in United States, France and 2 more
- Volunteers
- 110 people
- Sponsor
- Impax Laboratories, LLC
Parkinson Disease
A Study to Assess Pharmacokinetics (PK) of Preladenant in Participants With Chronic Renal Impairment (CRI) (P06512)
This is a two part study to compare the PK of preladenant administered to participants with CRI to the PK of preladenant administered to healthy participants.
- Trial name
- NCT01323855
- Testing
- Preladenant
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Parkinson's Disease
Imaging Biomarkers of Progression of Mobility Impairment in Parkinson Disease
The purpose of this research is to evaluate changes in cholinergic brain activity over time in subjects with Parkinson disease.
- Trial name
- NCT01106976
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Tardive Dyskinesia (TD)
Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia
This is a Phase 4, randomized, double-blind, placebo-controlled study to evaluate the persistence of effect of valbenazine 40 mg and 80 mg.
- Trial name
- NCT03891862
- Testing
- Valbenazine
- Where
- 43 sites in United States, Puerto Rico
- Volunteers
- 135 people
- Sponsor
- Neurocrine Biosciences
Parkinson Disease
Clinical Trial to Evaluate the Safety and Tolerability of Hydrogen in Patients With Parkinson's Disease
This study is a placebo-controlled, double-blind trial that will investigate the safety and tolerability of molecular hydrogen, a promising antioxidant agent, in patients with early-stage Parkinson's Disease.
- Trial name
- NCT03971617
- Testing
- Hydrogen
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Stony Brook University
Tourette Syndrome
Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
This is a Phase 2b, multicenter, open-label study to evaluate the safety and tolerability of optimized doses of NBI-98854 administered once daily for 24 weeks in pediatric subjects with Tourette Syndrome.
- Trial name
- NCT03444038
- Testing
- Valbenazine
- Where
- 37 sites in United States, Puerto Rico
- Volunteers
- 85 people
- Sponsor
- Neurocrine Biosciences
Parkinson Disease
Nintendo WII and Exercises at Rehabilitation of Individuals With Parkinson's Disease
Patients with Parkinson's disease present motor dysfunctions such as stiffness, tremor, postural instability and bradykinesia, which leads to alterations of balance, necessitating specialized physiotherapeutic treatment.
- Trial name
- NCT03235284
- Testing
- Exercises, Nintendo Wii, Exercises and Nintendo Wii
- Where
- Brazil
- Volunteers
- 45 people
- Sponsor
- Federal University of Bahia
Parkinson Disease, Overactive Bladder
Mirabegron in Parkinson Disease and Impaired Cognition
There is a high prevalence of OAB symptoms among patients with Parkinson's disease and a lack of pharmacotherapies with an acceptable side effect profile.
- Conditions
- Parkinson Disease, Overactive Bladder, Impaired Cognition
- Trial name
- MICT-PD (NCT02536976)
- Testing
- mirabegron
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- HealthPartners Institute
Huntington Chorea
Efficacy and Safety on SOM3355 in Huntington's Disease Chorea
Phase IIb, randomized, double-blind, placebo-controlled study in parallel groups assessing the efficacy and safety of two doses of SOM3355 in patients suffering from Huntington's Disease with choreic movements.
- Trial name
- NCT05475483
- Testing
- SOM3355 200 mg capsules, SOM3355 300 mg capsules
- Where
- 23 sites in France, Germany and 5 more
- Volunteers
- 139 people
- Sponsor
- SOM Innovation Biotech SA
Angelman Syndrome
A Trial of Levodopa in Angelman Syndrome
This study is designed to determine whether levodopa will lead to an improvement in the development and tremor in children with Angelman syndrome (AS).
- Trial name
- NCT01281475
- Testing
- Levodopa
- Where
- 7 sites in United States
- Volunteers
- 67 people
- Sponsor
- Wen-Hann Tan
Orthostatic Hypotension, Idiopathic Parkinson Disease
Lundbeck TOMs Orthostatic Hypotension
Orthostatic hypotension (OH), which consists in a significant reduction in blood pressure levels upon standing from a seated position, may affect approximately one in three patients with Parkinson's disease (PD).
- Trial name
- NCT04510922
- Testing
- Droxidopa 100 MG [Northera]
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Alberto Espay, MD, MSc
Parkinson Disease
LIFUP for Treatment of Motor Deficits in Parkinson's Disease
The study will test the feasibility of using Low Intensity Focused Ultrasound Pulsation (LIFUP) to treat motor symptoms in Parkinson's Disease (PD).
- Trial name
- LIFUP PD (NCT04593875)
- Testing
- Active LIFUP Treatment
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of California, Los Angeles
Parkinson's Disease
Genetic Influences on Response to Gait Rehabilitation in Parkinson's Disease
The aging Veteran population, together with high exposure to Agent Orange or other herbicides during military service, has made diseases such as Parkinson's disease (PD), currently affecting more than 80,000 Veterans, a major…
- Trial name
- Gen-Ex (NCT03607695)
- Testing
- Gait training
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- VA Office of Research and Development
Parkinsons Disease
A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease (MAESTRO)
The purpose of this study is to see if the study drug, Mirabegron, is safe and effective in treating symptoms of Overactive Bladder in people with Parkinson's Disease.
- Trial name
- Maestro (NCT02092181)
- Testing
- Mirabegron
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Daniel Burdick, MD
Parkinson's Disease
Patient- and Caregiver-reported Symptoms and Outcomes With Levodopa/Carbidopa Intestinal Gel for the Treatment of Advanced Parkinson's Disease
Patient reported outcomes (PRO) have become an important endpoint assessed in clinical trials. It is important to understand the relationship between medication and patients' symptomatology, quality of life and well-being.
- Trial name
- ADEQUA (NCT02289729)
- Volunteers
- 62 people
- Sponsor
- AbbVie